Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SHMT1 | P34896 | 6/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129850 | 0.90 | PTGER1 (0.60) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL5125104 | 0.88 | PTGER1 (0.66) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL14098716 | 0.88 | PTGER1 (0.53) | PTGER1KDM4EGAASMN1; SMN2LMNA | |
| SCHEMBL5115968 | 0.87 | PTGER1 (0.61) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL5121292 | 0.86 | PTGER1 (0.60) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL5119199 | 0.85 | PTGER1 (0.64) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL4721023 | 0.84 | PTGER1 (0.70) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL5123623 | 0.84 | PTGER1 (0.58) | PTGER1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL5129623 | 0.84 | PTGER1 (0.75) | PTGER1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL4724734 | 0.83 | PTGER1 (0.84) | PTGER1KDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885KDM4E 3212/4885ALDH1A1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.